Nilemdo (Bempedoic Acid)

Bempedoic acid blocks ATP citrate lyase, an enzyme early in the cholesterol synthesis pathway. This reduces hepatic cholesterol production and triggers up‑regulation of LDL receptors, which increases removal of LDL‑cholesterol from the bloodstream.

The specific dose of Nilemdo is determined by the prescribing healthcare professional based on the patient’s clinical condition, concomitant medications, and laboratory results. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Nilemdo in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the possible risk to the fetus or infant, and the decision should be made by a qualified clinician.

To order Nilemdo, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilemdo belongs to the ATP citrate lyase inhibitor class, which acts upstream of statins in the cholesterol pathway. Unlike statins, it is a pro‑drug activated in the liver and does not rely on HMG‑CoA reductase inhibition, offering an alternative mechanism for patients who need additional LDL‑C reduction.

Nilemdo tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Nilemdo is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious adverse events reported with Nilemdo include tendon rupture, severe hypersensitivity reactions such as angio‑edema, rhabdomyolysis, and acute liver failure. Patients should seek immediate medical attention if they experience unexplained muscle pain, swelling, jaundice, or signs of an allergic reaction.

Nilemdo is contraindicated in patients with known hypersensitivity to bempedoic acid or any of its excipients. It should also be avoided in individuals with severe liver disease or in those where the risk of tendon injury is high, unless a clinician determines that the benefits outweigh the risks.